Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (BK-01 adjuvant)
- Development stage
- Approved
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza vaccine (BK-01 adjuvant) is an adjuvanted split-virion influenza vaccine developed by Changchun BCHT Biotechnology Co. This biologic product is formulated with the company's proprietary BK-01 adjuvant technology, which is designed to enhance the immune response compared to non-adjuvanted vaccines. The vaccine contains 15 μg of hemagglutinin from each included influenza virus strain per 0.5 mL dose. It is currently being evaluated in Phase 1 clinical trials to assess its safety and immunogenicity in adults aged 18 years and older. The split-virion approach involves using inactivated virus particles that have been chemically disrupted, aiming to provide a balance of high immunogenicity and low reactogenicity.
- Other names
- BK-01 adjuvanted split-virion influenza vaccineBK01 adjuvanted split-virion influenza vaccineBK 01 adjuvanted split-virion influenza vaccineinfluenza virus vaccine (BK-01 adjuvant)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (BK-01 adjuvant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (BK-01 adjuvant).